Fermenta Board Approves INR 110 Crore Capex at Dahej for Plant-based Vitamin D3, Green Chemistry Enzyme, and Vitamin D3 Derivatives
Investment in new and expanded capacities for high-growth business verticalsCommercial-scale production of…
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 09, 2025 21:50 ET | Source: Wave Life Sciences USA, Inc.…
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
December 09, 2025 21:42 ET | Source: Dyne Therapeutics, Inc. WALTHAM, Mass.,…
The Frost & Sullivan Institute Honors Global Organizations Advancing Sustainable Progress with the 2025 Visionary Growth Leadership Best Practices Recognition
SANTA CLARA, Calif., Dec. 9, 2025 /PRNewswire/ -- The Frost & Sullivan…
HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND’S 185TH ANNIVERSARY
Punch commemorates its 185-year history with the launch of Punch Princesas Edición Limitada 2025, a new vitola that revives…
Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025 21:04 ET | Source: InnoCare Pharma BEIJING, Dec. 08,…
ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Manipal Hospitals Enhances Movement and Confidence Through Awareness on Movement Disorders
BENGALURU, India, Dec. 8, 2025 /PRNewswire/ -- Parkinson's disease often begins far…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9…